The overall aim of this proposal is to support the continuing development of the applicant as a research clinician and independent scientist in the field of drug abuse treatment. Two themes drive the applicant's work: 1) pharmacotherapies need to be developed that consider the heterogeneity of drug addicted samples and target specific subgroups, and 2) a better understanding of the biological and behavioral antecedents that contribute to drug abuse among certain vulnerable populations warrant investigation. Most medication development efforts to date have approached drug dependence as a unitary syndrome and have tested treatments in unselected samples. Many drug dependent individuals remain refractory or only partially responsive to this approach. Further, even among treatments with proven efficacy (e.g., methadone), certain subpopulations may do less well with these interventions and would benefit from a targeted intervention. During the proposed K02, the applicant will continue an ongoing line of inquiry by directing two studies to determine whether the identification and treatment of adult ADHD improves drug use outcome and psychopathology in opiate (DA-11444) and cocaine dependent (DA-11755) samples. Extending this approach to other comorbid disorders, the applicant will collaborate with junior investigators who are targeting ppharmacotherapies to nicotine- dependent schizophrenic patients, and marijuana and cocaine abusing individuals with schizophrenic and schizoaffective illness. Working with experienced investigators, the applicant plans to 1) use SPECT imaging to assess the neurobiologic dysfunction associated with ADHD and/or cocain abuse, and 2) better understand the sensitivity that vulnerable populations of women may have to alcohol and anxiolytic medications. Finally, the applicant will continue to contribute to a variety of educational activities and collaborate with young clinical investigators within the Division on Substance Abuse at Columbia University.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Scientist Development Award - Research (K02)
Project #
5K02DA000465-04
Application #
6616788
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Montoya, Ivan
Project Start
2000-08-16
Project End
2005-07-31
Budget Start
2003-08-01
Budget End
2004-07-31
Support Year
4
Fiscal Year
2003
Total Cost
$122,180
Indirect Cost
Name
Columbia University (N.Y.)
Department
Pathology
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Levin, Frances R; Mariani, John J; Pavlicova, Martina et al. (2016) Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 159:53-60
Kelly, Meredith A; Pavlicova, Martina; Glass, Andrew et al. (2014) Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR? Drug Alcohol Depend 144:42-6
Levin, Frances R; Mariani, John; Brooks, Daniel J et al. (2013) A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction 108:1084-94
Gunderson, Erik W; Levin, Frances R; Rombone, Margaret M et al. (2011) Improving temporal efficiency of outpatient buprenorphine induction. Am J Addict 20:397-404
Mariani, John J; Cheng, Wendy Y; Bisaga, Adam et al. (2011) Comparison of clinical trial recruitment populations: treatment-seeking characteristics of opioid-, cocaine-, and cannabis-using participants. J Subst Abuse Treat 40:426-30
Secora, Alex M; Eddie, David; Wyman, Bertram J et al. (2010) A comparison of psychosocial and cognitive functioning between depressed and non-depressed patients with cannabis dependence. J Addict Dis 29:325-37
Bisaga, Adam; Aharonovich, Efrat; Cheng, Wendy Y et al. (2010) A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. Drug Alcohol Depend 111:97-104
Gunderson, Erik W; Wang, Xin-Qun; Fiellin, David A et al. (2010) Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial. Addict Behav 35:537-40
Levin, Frances R; Mariani, John J; Secora, Alex et al. (2009) Atomoxetine Treatment for Cocaine Abuse and Adult Attention-Deficit Hyperactivity Disorder (ADHD): A Preliminary Open Trial. J Dual Diagn 5:41-56
Agosti, Vito; Levin, Frances R (2009) Does remission from alcohol and drug use disorders increase the likelihood of smoking cessation among nicotine dependent young adults? Soc Psychiatry Psychiatr Epidemiol 44:120-4

Showing the most recent 10 out of 36 publications